In this literature review, we aim to evaluate the impact of the different pharmacological therapies for acromegaly (first- and second-generation somatostatin receptor ligands, a GH receptor antagonist, and dopamine agonists) on glucose homeostasis and the underlying mechanisms through which they may exert these effects. Here, GHR is linked to acromegaly.